Clinical Trial Update: Proteomic Changes in Patients With Myasthenia Gravis and Ravulizumab

View source ↗

Summary

An update on a clinical trial studying proteomic changes in patients with Myasthenia Gravis treated with Ravulizumab, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Ravulizumab (ravulizumab)

Snippet

Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Conditions: Myasthenia Gravis Generalised | Status: NOT_YET_RECRUITING